logo-loader
Summit Therapeutics PLC

Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria

The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit

Summit
Summit will present data on the antibiotics in Amsterdam next week

Summit Therapeutics PLC (LON:SUMM) is set to expand its drug portfolio with a new antibiotics series designed to fight bacteria responsible for infections of the bloodstream, lungs and urinary tract.

The company plans to present data on the series of new mechanism antibiotics, called DDS-04, at the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam on April 13-16.

READ: Summit Therapeutics well backed for next phase of development

The DDS-04 series targets Enterobacteriaceae, a family of Gram-negative bacteria that includes Klebsiella pneumoniae and Escherichia coli, which can cause severe and often deadly infections.

Summit said DDS-04 has shown activity across a panel of K.pneumoniae and E. coli strains, including strains resistant to the antibiotics currently available. 

“The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit. 

“We look forward to developing the programme to show compelling clinical and economic data that offer significant advantages over standard of care for the patients in need.”

Quick facts: Summit Therapeutics PLC

Price: £0.20

Market: AIM
Market Cap: £32.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read